For AI agents: read the machine-readable documentation index at /llms.txt or the single-file full reference at /llms-full.txt.

§ 175.65 — Therapeutic Radiation Machines above 500 kV

New York City Administrative Code (current through L.L. 2026/147, enacted September 12, 2026, and amendments effective through October 10, 2026) · 24 RCNY § 175.65

Corpus is an independent public-information project, not the official City of New York website. Stable reference: corpuslaw.us/code/441d2f47-f64f-4069-ab63-2b0a34834afa

§ 175.65 Therapeutic Radiation Machines above 500 kV.

This section applies to photon therapy systems capable of operating at 500 kV and above, electron therapy systems capable of operating at 500 keV and above, and proton therapy systems. (a) Possession of survey instrument. Each facility location authorized to use a therapeutic radiation machine subject to this section must possess appropriately calibrated portable monitoring equipment. At a minimum, such equipment must include a portable radiation measurement survey instrument capable of measuring dose rates over the range 10 µSv (1 mrem) per hour to 10 mSv (1,000 mrem) per hour. The survey instrument must be operable and calibrated in accordance with 24 RCNY Health Code § 175.66. (b) Leakage radiation outside the maximum useful beam in photon and electron modes. (1) The absorbed dose due to leakage radiation (excluding neutrons) at any point outside the maximum sized useful beam, but within a circular plane of radius 2 meters which is perpendicular to and centered on the central axis of the useful beam at the nominal treatment distance (i.e. patient plane), must not exceed a maximum of 0.2 percent and an average of 0.1 percent of the absorbed dose on the central axis of the beam at the nominal treatment distance. Measurements must be averaged over an area not exceeding 100 square centimeters (100 cm2) at a minimum of 16 points uniformly distributed in the plane; (2) Except for the area defined in paragraph (1) of this subdivision, the absorbed dose due to leakage radiation (excluding neutrons) at 1 meter from the electron path between the electron source and the target or electron window must not exceed 0.5 percent of the absorbed dose on the central axis of the beam at the nominal treatment distance. Measurements must be averaged over an area not exceeding 100 square centimeters (100 cm2); (3) For equipment manufactured after July 1, 2019, the neutron absorbed dose outside the useful beam must comply with International Electrotechnical Commission (IEC) Document 60601-2-1 (or the most current revision or successor national standard); and (4) For each therapeutic radiation machine, the registrant must determine, or obtain from the manufacturer, the leakage radiation existing at the positions specified in paragraphs (1) and (2) of this subdivision for the specified operating conditions. Records on leakage radiation measurements must be maintained at the installation for inspection by the Department. (c) Leakage radiation through beam limiting devices. (1) Photon radiation. All adjustable jaws type beam limiting devices must attenuate the useful beam such that at the nominal treatment distance, the maximum absorbed dose anywhere in the area shielded by the beam limiting device must not exceed 2 percent of the maximum absorbed dose on the central axis of the useful beam measured in a 100 cm2 radiation field, or maximum available field size if less than 100 cm2. (2) Electron radiation. All adjustable or interchangeable electron applicators must attenuate the radiation, including but not limited to photon radiation generated by electrons incident on the beam limiting device and electron applicator and other parts of the radiation head, such that the absorbed dose in a plane perpendicular to the central axis of the useful beam at the nominal treatment distance must not exceed: (i) a maximum of 2 percent and average of 0.5 percent of the absorbed dose on the central axis of the useful beam at the nominal treatment distance. This limit applies beyond a line 7 centimeters outside the periphery of the useful beam; and (ii) a maximum of 10 percent of the absorbed dose on the central axis of the useful beam at the nominal treatment distance. This limit applies beyond a line 2 centimeters outside the periphery of the useful beam. (3) Skyshine radiation. The exposure due to neutron and photon emissions scattered outside the facility must be calculated using industry standard methods. (4) Measurement of leakage radiation. (i) Photon radiation. Measurements of leakage radiation through the beam limiting devices must be made with the beam limiting devices closed and any residual aperture blocked by at least 2-tenth value layers of suitable absorbing material. In the case of overlapping beam limiting devices, the leakage radiation through each set must be measured independently at the depth of maximum dose. Measurements must be made using a radiation detector of area not exceeding 10 square centimeters (10 cm2). (ii) Electron radiation. Measurements of leakage radiation through the electron applicators must be made with the electron beam directed into the air and using a radiation detector of area up to but not exceeding 1 square centimeter suitably protected against radiation which has been scattered from material beyond the radiation detector. Measurements must be made using 1 centimeter of water equivalent build up material. (d) Filters/wedges. (1) Each wedge filter that is removable from the system must be clearly marked with an identification number. For removable wedge filters, the nominal wedge angle must appear on the wedge or wedge tray (if permanently mounted to the tray). If the wedge or wedge tray is significantly damaged, the wedge transmission factor must be re-measured. (2) If the absorbed dose rate information required by subdivision (i) of this section relates exclusively to operation with a field flattening filter or beam scattering foil in place, such foil or filter must be removable only by the use of tools. (3) For equipment which utilizes wedge filters manufactured after July 1, 2019, interchangeable field flattening filters, or interchangeable beam scattering foils, the following apply: (i) irradiation must not be possible until a selection of a filter or a positive selection to use "no filter" has been made at the treatment control panel, either manually or automatically; (ii) an interlock system must be provided to prevent irradiation if the filter selected is not in the correct position; (iii) a display must be provided at the treatment control panel showing the wedge filter, interchangeable field flattening filters, or interchangeable beam scattering foils in use; and (iv) an interlock must be provided to prevent irradiation if any filter or beam scattering foil selection operation carried out in the treatment room does not agree with the filter or beam scattering foil selection operation carried out at the treatment control panel. (e) Stray radiation in the useful beam. For equipment manufactured after July 1, 2019, the registrant must determine during acceptance testing, or obtain from the manufacturer, data sufficient to ensure that x-ray stray radiation in the useful electron beam, absorbed dose at the surface during x-ray irradiation and stray neutron radiation in the useful x-ray beam comply with International Electrotechnical Commission (IEC) Document 60601-2-1 (or the most current revision or successor national standard). (f) Beam monitors. All therapeutic radiation machines subject to the requirements of this section must be provided with redundant beam monitoring systems. The sensors for these systems must be fixed in the useful beam during treatment to indicate the dose monitor unit rate. (1) Equipment manufactured after July 1, 2019 must be provided with at least 2 independently powered integrating dose meters. Alternatively, common elements may be used if the production of radiation is terminated upon failure of any common element. (2) Equipment manufactured on or before July 1, 2019 must be provided with at least 1 radiation detector. This detector must be incorporated into a useful beam monitoring system. (3) The detector and the system into which that detector is incorporated must meet the following requirements: (i) each detector must be removable only with tools and, if movable, must be interlocked to prevent incorrect positioning; (ii) each detector must form part of a beam monitoring system from whose readings in dose monitor units the absorbed dose at a reference point can be calculated; (iii) each beam monitoring system must be capable of independently monitoring, interrupting, and terminating irradiation; and (iv) for equipment manufactured after July 1, 2019, the design of the beam monitoring systems must ensure that the: (A) malfunctioning of one system must not affect the correct functioning of the other systems; and (B) failure of either system must terminate irradiation or prevent the initiation of radiation. (v) each beam monitoring system must have a legible display at the treatment control panel. For equipment manufactured after July 1, 2019, each display must: (A) maintain a reading until intentionally reset; (B) have only one scale and no electrical or mechanical scale multiplying factors; (C) utilize a design such that increasing dose is displayed by increasing numbers; and (D) in the event of power failure, the beam monitoring information required by subparagraph (v) of paragraph (3) of this subdivision displayed at the control panel at the time of failure must be retrievable in at least one system for a 20 minute period of time. (g) Beam symmetry. (1) A bent-beam linear accelerator with beam flattening filters subject to the requirements of this section must be provided with auxiliary devices to monitor beam symmetry; (2) The devices referenced in paragraph (1) of this subdivision must be able to detect field asymmetry greater than 10 percent; and (3) The devices referenced in paragraph (1) of this subdivision must be configured to terminate irradiation if the specifications in paragraph (2) of this subdivision cannot be maintained. (h) Selection and display of dose monitor units. (1) Irradiation must not be possible until a new selection of a number of dose monitor units has been made at the treatment control panel. (2) The pre-selected number of dose monitor units must be displayed at the treatment control panel until reset manually for the next irradiation. (3) After termination of irradiation, it must be necessary to reset the dosimeter display before subsequent treatment can be initiated. (4) For equipment manufactured after July 1, 2019 after termination of irradiation, it must be necessary for the operator to reset the pre-selected dose monitor units before irradiation can be initiated. (i) Air kerma rate/absorbed dose rate. For equipment manufactured after July 1, 2019, a system must be provided from whose readings the air kerma rate or absorbed dose rate at a reference point can be calculated. In addition, the following requirements apply: (1) the dose monitor unit rate must be displayed at the treatment control panel; (2) if the equipment can deliver under any conditions an air kerma rate or absorbed dose rate at the nominal treatment distance more than twice the maximum value specified by the manufacturer, a device must be provided which terminates irradiation when the air kerma rate or absorbed dose rate exceeds a value twice the specified maximum. The registrant must maintain a record of dose rate at which the irradiation will be terminated; (3) if the equipment can deliver under any fault conditions an air kerma rate or absorbed dose rate at the nominal treatment distance more than 10 times the maximum value specified by the manufacturer, a device must be provided to prevent the air kerma rate or absorbed dose rate anywhere in the radiation field from exceeding twice the specified maximum value and to terminate irradiation if the excess absorbed dose at the nominal treatment distance exceeds 4 Gy (400 rad); and (4) for each therapeutic radiation machine, the registrant must determine, or obtain from the manufacturer, the maximum values specified in paragraphs (2) and (3) of 24 RCNY Health Code § 175.65(i) for the specified operating conditions. Records of these maximum values must be maintained at the installation for inspection by the Department. (j) Termination of irradiation by the beam monitoring system or systems during stationary beam radiation therapy. (1) Each primary system must terminate irradiation when the pre-selected number of dose monitor units has been detected by the system. (2) If the original design of the equipment included a secondary dose monitoring system, that system must be capable of terminating irradiation when not more than 15 percent or 40 dose monitor units above the pre-selected number of dose monitor units set at the control panel has been detected by the secondary dose monitoring system. (3) For equipment manufactured after July 1, 2019, an indicator on the control panel must show which monitoring system has terminated irradiation. (k) Termination of irradiation. It must be possible to terminate irradiation and equipment movement or go from an interruption condition to termination condition at any time from the operator's position at the treatment control panel. (l) Interruption of irradiation. If a therapeutic radiation machine has an interrupt mode, it must be possible to interrupt irradiation and equipment movements at any time from the treatment control panel. Following an interruption, it must be possible to restart irradiation by operator action without any reselection of operating conditions. If any change is made of a pre- selected value during an interruption, irradiation and equipment movements must be automatically terminated. (m) Timer. A suitable irradiation control device must be provided to terminate the irradiation after a pre-set time interval. (1) A timer must be provided which has a display at the treatment control panel. The timer must have a pre-set time selector and an elapsed time indicator. (2) The timer must be a cumulative timer that activates with an indication of "BEAM-ON" and retains its reading after irradiation is interrupted or terminated. After irradiation is terminated and before irradiation can be reinitiated, it must be necessary to reset the elapsed time indicator. (3) The timer must terminate irradiation when a pre-selected time has elapsed, if the dose monitoring systems have not previously terminated irradiation. (n) Selection of radiation type. Equipment capable of both x-ray therapy and electron therapy must meet the following additional requirements: (1) irradiation must not be possible until a selection of radiation type (x-rays or electrons) has been made at the treatment control panel; (2) the radiation type selected must be displayed at the treatment control panel before and during irradiation; (3) an interlock system must be provided to: (i) ensure that the equipment can principally emit only the radiation type that has been selected; (ii) prevent irradiation with x-rays, except to obtain an image, when electron applicators are fitted; (iii) prevent irradiation with electrons when accessories specific for x- ray therapy are fitted; and (iv) prevent irradiation if any selected operations carried out in the treatment room do not agree with the selected operations carried out at the treatment control panel. (o) Selection of energy. Equipment capable of generating radiation beams of different energies must meet the following requirements: (1) irradiation must not be possible until a selection of energy has been made at the treatment control panel; (2) the nominal energy value selected must be displayed at the treatment control panel until reset manually for the next irradiation. After termination of irradiation, it must be necessary to reset the nominal energy value selected before subsequent treatment can be initiated; (3) irradiation must not be possible until the appropriate flattening filter or scattering foil for the selected energy is in its proper location; and (4) for equipment manufactured after July 1, 2019, the selection of energy must comply with International Electrotechnical Commission (IEC) Document 60601-2-1 (or the most current revision or successor national standard). (p) Selection of stationary beam radiation therapy or moving beam radiation therapy. Therapeutic radiation machines capable of both stationary beam radiation therapy and moving beam radiation therapy must meet the following requirements: (1) irradiation must not be possible until a selection of stationary beam radiation therapy or moving beam radiation therapy has been made at the treatment control panel; (2) the mode of operation must be displayed at the treatment control panel; (3) an interlock system must be provided to ensure that the equipment can operate only in the mode that has been selected; (4) an interlock system must be provided to prevent irradiation if any selected parameter in the treatment room does not agree with the selected parameter at the treatment control panel; (5) moving beam radiation therapy must be controlled to obtain the selected relationships between incremental dose monitor units and incremental movement. For equipment manufactured after July 1, 2019: (i) an interlock system must be provided to terminate irradiation if the number of dose monitor units delivered in any 10 degrees of rotation or 1 cm of linear motion differs by more than 20 percent from the selected value; (ii) where angle terminates the irradiation in moving beam radiation therapy, the dose monitor units delivered must differ by less than 5 percent from the dose monitor unit value selected; (iii) an interlock must be provided to prevent motion of more than 5 degrees or 1 cm beyond the selected limits during moving beam radiation therapy; (iv) an interlock must be provided to require that a selection of direction be made at the treatment control panel in all units which are capable of both clockwise and counter-clockwise moving beam radiation therapy; and (v) moving beam radiation therapy must be controlled with both primary position sensors and secondary position sensors to obtain the selected relationships between incremental dose monitor units and incremental movement. (6) Where the beam monitor system terminates the irradiation in moving beam radiation therapy, the termination of irradiation must be as required by subdivision (j) of this section. (7) For equipment manufactured after July 1, 2019, an interlock system must be provided to terminate irradiation if movement: (i) occurs during stationary beam radiation therapy; or (ii) does not start or stops during moving beam radiation therapy unless such stoppage is a pre-planned function. (q) Facility design requirements for therapeutic radiation machines operating above 500 kV. In addition to the shielding requirements of 24 RCNY Health Code § 175.67, the following design elements are required: (1) Protective barriers. All protective barriers must be fixed, except for access doors to the treatment room or movable beam interceptors. (2) Control panel. In addition to other requirements specified in this Article, the control panel must also: (i) be located outside the treatment room; (ii) provide an indication of whether electrical power is available at the control panel and if activation of the radiation is possible; (iii) provide an indication of whether radiation is being produced; and (iv) include an access control (locking) device that will prevent unauthorized use of the therapeutic radiation machine. (3) Viewing systems. Windows, mirrors, closed-circuit television or an equivalent viewing system must be provided to permit continuous observation of the patient following positioning and during irradiation and must be so located that the operator may observe the patient from the treatment control panel. The therapeutic radiation machine must not be used for patient irradiation unless at least one viewing system is operational. (4) Aural communications. Provision must be made for continuous two-way aural communication between the patient and the operator at the control panel. The therapeutic radiation machine must not be used for irradiation of patients unless continuous two-way aural communication is possible. (5) Room entrances. Treatment room entrances must be provided with warning lights in a readily observable position near the outside of all access doors, which will indicate when the useful beam is "ON" and when it is "OFF". (6) Entrance interlocks. Interlocks must be provided such that all access controls are activated before treatment can be initiated or continued. If the radiation beam is interrupted by any access control, it must not be possible to restore the machine to operation without resetting the access control and reinitiating irradiation by manual action at the control panel. (7) Beam interceptor interlocks. If the shielding material in any protective barrier requires the presence of a beam interceptor to ensure compliance with this Article, interlocks must be provided to prevent the production of radiation, unless the beam interceptor is in place, whenever the useful beam is directed at the designated barrier. (8) Emergency cutoff switches. At least 1 emergency power cutoff switch must be located in the radiation therapy room and must terminate all equipment electrical power including radiation and mechanical motion. This switch is in addition to the termination switch required by subdivision (k) of this section. All emergency power cutoff switches must include a manual reset so that the therapeutic radiation machine cannot be restarted from the unit's control console without resetting the emergency cutoff switch. (9) Safety interlocks. All safety interlocks must be designed so that any defect or component failure in the safety interlock system prevents or terminates operation of the therapeutic radiation machine. (10) Surveys for residual radiation. Surveys for residual activity must be conducted on all therapeutic radiation machines capable of generating photon and electron energies, or proton energies above 10 MV prior to machining, removing, or working on therapeutic radiation machine components which may have become activated due to photo- neutron production. (11) Applicants for proton therapy systems capable of operating at 500 keV and above must present documentation of shielding design adequate as determined by the Department to meet the requirements of 24 RCNY Health Code § 175.67. An independent consultant qualified in proton shielding calculation with proven experience in applicable computer simulation, not involved in the original design and with prior approval by the Department must be hired by the applicant to perform an independent verification of the proposed shielding design using site specific equipment and data or information. The independent consultant must prepare a report evaluating the correctness and completeness of the original shielding design calculation, and the adequacy of the shielding design to satisfy the requirements of 24 RCNY Health Code § 175.67. The independent consultant's report must be submitted to the Department by the applicant as an addendum to the application. (r) QMP support. (1) The services of a QMP must be required in facilities having therapeutic radiation machines with energies of 500 kV and above. The QMP must be responsible for: (i) full calibrations required by subdivision (t) of this section and protection surveys required by 24 RCNY Health Code § 175.61(a); (ii) supervision and review of patient dosimetry; (iii) beam data acquisition and transfer for computerized dosimetry, and supervision of its use; (iv) quality assurance, including quality assurance check review required by paragraph (5) of subdivision (u) of this section; (v) consultation with the authorized user in treatment planning, as needed; and (vi) perform calculations/assessments regarding medical events. (2) If the QMP is not a full-time employee of the registrant, the operating procedures required by subdivision (s) of this section must also specifically address how the QMP is to be contacted for problems or emergencies, as well as the specific actions, if any, to be taken until the QMP can be contacted. (3) Notwithstanding other provisions of this Article, the QMP named on the certified registration for a proton therapy machine described in this section must be a full-time employee of the registrant. (s) Operating procedures. (1) No individual, other than the patient, must be in the treatment room during treatment or during any irradiation for testing or calibration purposes. (2) Therapeutic radiation machines must not be made available for medical use, unless the requirements of subdivision (a) of 24 RCNY Health Code § 175.61 and subdivisions (t) and (u) of this section have been met. (3) Therapeutic radiation machines, when not in operation, must be secured to prevent unauthorized use. (4) When adjustable beam limiting devices are used, the position and shape of the radiation field must be indicated by a light field. (5) If a patient must be held in position during treatment, mechanical supporting or restraining devices must be used. (6) A copy of the current operating and emergency procedures must be maintained at the therapeutic radiation machine control console. (t) Acceptance testing, commissioning and full calibration measurements. (1) Acceptance testing, commissioning and full calibration of a therapeutic radiation machine subject to this section must be performed by, or under the direct supervision of, a QMP. (2) Acceptance testing and commissioning must be performed in accordance with "AAPM Code of Practice for Radiotherapy Accelerators: AAPM Report No. 47", prepared by Radiation Therapy Task Group 45 (or the most current revision or successor national standard) and the manufacturer's contractual specifications. Acceptance testing and commissioning must be conducted before the first medical use following installation or reinstallation of the therapeutic radiation machine. (3) Full calibration for photon therapy systems capable of operating at 500 kV and above or electron therapy systems capable of operating at 500 keV and above must include measurement of all applicable parameters required by Table II of the "Comprehensive QA for Radiation Oncology: Report of AAPM Radiation Therapy: AAPM Report No. 46," prepared by Committee Task Group 40 and must be performed in accordance with "AAPM Code of Practice for Radiotherapy Accelerators: AAPM Report No. 47" prepared by Radiation Therapy Task Group 45 (or the most current revision or successor national standard). Although it is not necessary to complete all elements of a full calibration at the same time, all applicable parameters (for all energies) must be completed at intervals not exceeding 12 calendar months, unless a more frequent interval is required in Table II. (4) For proton therapy systems capable of operating at 500 keV and above, full calibration must include measurement of all applicable parameters. The certified registrant must submit their full calibration protocol to the Department for review and approval. (5) The QMP must perform all elements of a full calibration necessary to determine that all parameters are within acceptable limits when the following apply: (i) Whenever quality assurance check measurements indicate that the radiation output differs by more than 5 percent from the value obtained at the last full calibration and the difference cannot be reconciled. Therapeutic radiation machines with multi-energy or multi-mode capabilities shall only require measurements for those modes or energies that are not within their acceptable range. (ii) Following any component replacement, major repair, or modification of components that could significantly affect the characteristics of the radiation beam. If the repair, replacement or modification does not affect all modes or energies, measurements must be performed on the effected mode/energy that is in most frequent clinical use at the facility. The remaining energies/modes may be validated with quality assurance check procedures against the criteria in subparagraph (i) of this paragraph (5) of this subdivision (t) of this section. (6) The registrant must maintain a record of each calibration in an auditable form for the duration of the registration. The record must include: (i) the date of the calibration, the manufacturer's name, model and serial number or other unambiguous identification of the therapeutic radiation machine along with the instrument's certificate of calibration and; (ii) all measured beam output data collected during the calibration and the derivation for all the correction factors (as delineated in AAPM Reports TG 21 or TG 51 or any successor publication or national standard) applied to the measured beam output data in the calculation of the therapeutic radiation machine's beam output dose rate (the latter must be conducted for each photon and electron beam clinically utilized at the facility). (iii) for photon or electron therapy machines, the derivation of all the correction factors applied to the measured beam output data in the calculation of the therapeutic radiation machine's beam output dose rate (as delineated in AAPM Reports TG 21 or TG 51 or any successor publication or national standard) or; (iv) for proton therapy machines, derivation for all the correction factors applied to the measured beam output data in the calculation of the therapeutic radiation machine's beam output dose rate (as delineated in the registrant's calibration protocol). The certified registrant's calibration protocol in the case of proton therapy machines must be submitted to Department for review and approval. (u) Periodic quality assurance checks. (1) Periodic quality assurance checks must be performed on all therapeutic radiation machines subject to this section. To satisfy this requirement, quality assurance checks must include a determination of all parameters for periodic quality assurance checks and at the intervals contained in AAPM Task Group 142 report: "Quality assurance of medical accelerators" (2009) (or the most current revision or successor national standard) for photon therapy systems capable of operating at 500 kV and above or electron therapy systems capable of operating at 500 keV and above. (2) The registrant must use a dosimetry system that has been compared within the previous 12 months with the dosimetry system described in 24 RCNY Health Code § 175.61(c)(1) to make the periodic quality assurance checks required by paragraph (1) of this subdivision; (3) The registrant must perform periodic quality assurance checks required by paragraph (1) of this subdivision in accordance with procedures established by the QMP; (4) The registrant must review the results of each periodic radiation output check according to the following procedures: (i) the QMP must be immediately notified if any parameter is not within its acceptable tolerance. The therapeutic radiation machine must not be made available for subsequent medical use until the QMP has determined that all parameters are within their acceptable tolerances; (ii) if all quality assurance check parameters appear to be within their acceptable range, the quality assurance check must be reviewed and signed by either the authorized user or QMP within 3 treatment days; and (iii) the QMP must review and sign the results of each radiation output quality assurance check at intervals not to exceed 30 days. (5) Therapeutic radiation machines subject to the requirements of this section must have applicable safety quality assurance checks listed in AAPM Task Group 142 report: "Quality assurance of medical accelerators" (2009) (or the most current revision or successor national standard) performed at intervals not to exceed 1 week; (6) To satisfy the requirement of paragraph (5) of this subdivision, safety quality assurance checks must ensure proper operation of: (i) electrical interlocks at each external beam radiation therapy room entrance; (ii) proper operation of the "BEAM-ON", interrupt and termination switches; (iii) beam condition indicator lights on the access doors, control console, and in the radiation therapy room; (iv) viewing systems; (v) electrically operated treatment room doors from inside and outside the treatment room; (7) The registrant must annually perform checks to ensure proper operation of all emergency power cutoff switches, or documentation of proper operation of emergency power cutoff switches must be provided by the manufacturer as confirmed during preventative maintenance. (8) The registrant must promptly repair any system identified in paragraph (6) or (7) of this subdivision that is not operating properly (9) The registrant must maintain a record of each quality assurance check required by paragraphs (1), (6), and (7) of this subdivision for 3 years. The record must include: (i) the date of the quality assurance check; (ii) the manufacturer's name, model number, and serial number of the therapeutic radiation machine; (iii) the manufacturer's name, model number and serial number for the instruments used to measure the radiation output of the therapeutic radiation machine; and (iv) the signature of the individual who performed the quality assurance check. (v) Possession of survey instruments. (1) Each facility location authorized to use a therapeutic radiation machine in accordance with 24 RCNY Health Code § 175.65 must possess appropriately calibrated portable monitoring equipment. At a minimum, such equipment must include a portable radiation measurement survey instrument capable of measuring dose rates over the range of 10 µSv (1 mrem) per hour to 10 mSv (1,000 mrem) per hour. The survey instruments must be operable and calibrated in accordance with 24 RCNY Health Code § 175.66. (2) Each facility location authorized to use a proton therapeutic radiation machine must possess appropriately calibrated portable neutron radiation measuring equipment in accordance with 24 RCNY Health Code § 175.66. (w) Quality assurance checks for Intensity-Modulated Radiation Therapy (IMRT) must: (1) include commissioning and testing of the treatment planning and delivery systems, routine quality assurance of the delivery system, and patient-specific validation of treatment plans; and (2) be performed in accordance with "Guidance document on delivery, treatment planning, and clinical implementation of IMRT: Report of the IMRT subcommittee of the AAPM radiation therapy committee: AAPM Report No. 82" (or the most current revision or successor national standard); and (3) be performed in accordance with the manufacturer's specifications. (Added City Record 4/24/2019, eff. 5/24/2019)

Ask a question about New York law

Corpus searches the New York sections it holds and shows the ones that match, with their citations. Free, no sign-in.